Role of Heat Shock Protein 70 as a Therapeutic Target in T-Cell Lymphomas
Official title: Role of Heat Shock Protein 70 as a Mediator and Therapeutic Target in T-cell Lymphomas
Funded at University of Tx Md Anderson Can Ctr · NIH-11364981 · Data updated 2026-11-12
A clinical-relevance study explores a new targeted therapy for difficult-to-treat T-cell lymphomas by focusing on a protein called HSP70.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Tx Md Anderson Can Ctr NIH-funded |
| Lab location | 1 site (Houston, United States) |
| Project start | July 20, 2022 |
| Project end | June 30, 2027 |
| Funding year | 2026 |
| Award (this year) | $483,912 |
| NIH project number | 5R01CA266612-05 |
| Project ID | NIH-11364981 on NIH RePORTER |
Who could benefit from this research
✓Could help
Adults with peripheral T-cell lymphoma (PTCL) or cutaneous T-cell lymphoma (CTCL) who express HSP70 on their malignant cells and are candidates for antibody-drug conjugate therapies.
✕Less likely to help
Patients whose tumors do not express surface HSP70 or who cannot tolerate antibody-drug conjugates may not benefit.
What this research studies
This project examines how a specific protein, HSP70, appears on the surface of certain T-cell lymphoma cells and whether an antibody-drug conjugate against it can stop cancer cell growth. Researchers developed a monoclonal antibody that binds HSP70 on malignant T-cells and linked it to a potent anti-cancer payload to test its therapeutic potential. The work includes preclinical laboratory studies using lymphoma cell lines to assess efficacy and safety signals that could guide future clinical testing. If successful, the findings could pave the way for new targeted treatments for PTCL and CTCL patients who currently have limited options.
Why it matters
Potential benefit: If successful, patients with peripheral and cutaneous T-cell lymphomas could have a new, targeted therapy option.
How similar studies have gone: Prior studies showed that targeting HSP70 with antibodies can inhibit growth in lymphoma models, supporting continued development.
Where this research is happening
-
University of Tx Md Anderson Can Ctr
Houston, United States Active
Researchers
- Principal investigator: Orlowski, Robert Zygmunt — University of Tx Md Anderson Can Ctr
- Study coordinator: Orlowski, Robert Zygmunt
Related research
Other NIH-funded projects on the same topics.
-
Pragmatic midodrine trial to reduce ICU vasopressor use in septic shock
A practical, patient-focused trial tests whether taking oral midodrine can lessen the need for IV vasopressors and shorten ICU stays for people with sepsis-related low blood pressure.
-
Understanding how small heat shock proteins protect our cells
A study from the University of Washington explores how tiny chaperone proteins protect eye and other cells from damage, which could help prevent conditions like cataracts and age-related macular degeneration.
-
A new approach to freeing HIV from brain cells and reducing brain inflammation
A patient-focused approach tests a strategy to flush out hidden HIV in the brain and protect brain health by reducing inflammation.
-
Shock patients: better, faster teamwork to find the cause
A team of clinicians works together to quickly identify the exact cause of a patient’s shock to guide the right treatment.
-
Multi-scale model to improve REBOA use in hemorrhagic shock
A researcher team is building a computer model to better predict how to use REBOA, a device that can control bleeding in the torso, so patients with severe trauma may survive.
-
Phospholipid nanoparticle fluid to replace blood volume and protect organs in severe bleeding
A new, bubble-free fluid made of tiny lipid particles is being developed to quickly restore blood volume and protect organs during severe bleeding when real blood isn’t available.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.